Group 1 - The company, Netcapital Inc., closed a registered direct offering for the purchase and sale of 714,286 shares of common stock at a price of $7.00 per share, generating approximately $5 million in gross proceeds [1][3] - In a concurrent private placement, the company issued unregistered short-term warrants to purchase up to 714,286 shares at an exercise price of $6.88 per share, potentially adding up to $4.9 million in gross proceeds if fully exercised [1][3] - The net proceeds from the offering will be used for the repayment of certain outstanding promissory notes and for general working capital purposes [3] Group 2 - H.C. Wainwright & Co. acted as the exclusive placement agent for the offering [2] - The common stock was offered under a "shelf" registration statement that was declared effective by the SEC on October 26, 2022 [4] - The unregistered short-term warrants were offered in a private placement under Section 4(a)(2) of the Securities Act and have not been registered under the Securities Act or applicable state securities laws [5] Group 3 - Netcapital Inc. is a fintech company that provides a scalable technology platform for private companies to raise capital online and offers private equity investment opportunities to investors [7] - The company's consulting group, Netcapital Advisors, provides marketing and strategic advice and takes equity positions in select companies [7] - The company's funding portal is registered with the SEC and is a member of FINRA, and its broker-dealer is also registered with the SEC and a member of FINRA [7]

Core Points - Netcapital Inc. has announced a registered direct offering of 714,286 shares of common stock at a price of $7.00 per share, with expected gross proceeds of approximately $5 million [1][3] - The company will also issue unregistered short-term warrants to purchase up to 714,286 shares at an exercise price of $6.88, potentially generating an additional $4.9 million if fully exercised [1][3] - The offering is expected to close around July 7, 2025, subject to customary closing conditions [1] Financial Details - The gross proceeds from the offering are anticipated to be about $5 million before deducting fees and expenses [3] - If the unregistered short-term warrants are fully exercised, the potential additional gross proceeds will be approximately $4.9 million [3] - The net proceeds from the offering will be used for repaying certain outstanding promissory notes and for general working capital purposes [3] Regulatory Information - The common stock is being offered under a "shelf" registration statement that was declared effective by the SEC on October 26, 2022 [4] - The unregistered short-term warrants are being offered in a private placement and have not been registered under the Securities Act [5] Company Overview - Netcapital Inc. is a fintech company that provides a platform for private companies to raise capital online and offers private equity investment opportunities [7] - The company operates a registered funding portal and has a broker-dealer that is a member of FINRA [7]

Core Viewpoint - Curis, Inc. has announced a definitive agreement for a registered direct offering and concurrent private placement, aiming to raise approximately $7.0 million to support its research and development efforts [1][2]. Group 1: Offering Details - Curis will issue 1,538,460 shares of common stock at a market price, along with unregistered pre-funded warrants and common warrants [1]. - The pre-funded warrants will allow investors to purchase an additional 1,538,461 shares at an exercise price of $0.01, while common warrants will allow for the purchase of 3,076,921 shares at an exercise price of $2.15 [1]. - The combined purchase price for one share and the associated common warrant is $2.275, and for one pre-funded warrant and the associated common warrant is $2.265 [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for research, development, working capital, and other general corporate purposes [2]. Group 3: Closing and Agents - The registered direct offering and concurrent private placement are expected to close on or about July 3, 2025, pending customary closing conditions [2]. - Laidlaw & Company (U.K.) Ltd. and Jones are acting as placement agents for the offerings [3]. Group 4: Regulatory Information - The shares are being offered under a shelf registration statement filed with the SEC, and a prospectus supplement will be available on the SEC's website [4]. - The unregistered warrants are being offered under an exemption from registration requirements, and Curis will file a resale registration statement with the SEC for the underlying shares [5]. Group 5: Company Overview - Curis is focused on developing emavusertib, an orally available IRAK4 inhibitor, currently in various clinical studies for treating relapsed/refractory cancers [7][8]. - Emavusertib has received Orphan Drug Designation from the FDA for multiple cancer treatments [8].

Core Viewpoint - Univest Securities, LLC has successfully closed a registered direct offering for Ostin Technology Group Co., Ltd., raising approximately $5 million through the sale of 41,666,667 Class A ordinary shares at a price of $0.12 per share [1][2][3]. Group 1: Offering Details - The offering involved a single institutional investor purchasing an aggregate of 41,666,667 Class A ordinary shares or pre-funded warrants at a purchase price of $0.12 per share [2]. - The gross proceeds from this offering amounted to approximately $5 million [3]. - The offering was conducted under a shelf registration statement on Form F-3, which was declared effective by the SEC on May 28, 2024 [4]. Group 2: Company Background - Ostin Technology Group Co., Ltd. is a supplier of display modules and polarizers based in China, founded in 2010 [7]. - The company specializes in designing, developing, and manufacturing TFT-LCD display modules used in consumer electronics, outdoor LCD displays, and automotive displays [7]. - Ostin also manufactures polarizers that are utilized in its TFT-LCD display modules [7]. Group 3: Univest Securities Overview - Univest Securities, LLC is a full-service investment bank and securities broker-dealer firm based in New York, registered with FINRA since 1994 [6]. - The firm has raised over $1.3 billion in capital for issuers globally since 2019 and has completed approximately 100 transactions across various industries [6].

Core Viewpoint - Robin Energy Ltd. has announced a securities purchase agreement to sell 763,000 common shares at $5.25 each, aiming for gross proceeds of approximately $4.0 million before expenses [1][2]. Group 1: Offering Details - The offering is being facilitated by Maxim Group LLC as the sole placement agent [2]. - The expected closing date for the offering is around June 20, 2025, pending customary closing conditions [2]. - The offering is conducted under an effective shelf registration statement on Form F-3, filed with the SEC on April 28, 2025 [3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and general corporate purposes [2]. Group 3: Company Overview - Robin Energy is an international ship-owning company that provides energy transportation services globally, currently owning one Handysize tanker vessel for petroleum product transportation [5].

Core Viewpoint - Robin Energy Ltd. has announced a securities purchase agreement to sell 860,000 common shares at $5.25 each, aiming for gross proceeds of approximately $4.5 million, which will be used for working capital and general corporate purposes [1][2]. Group 1: Offering Details - The offering is being facilitated by Maxim Group LLC as the sole placement agent [2]. - The expected closing date for the offering is around June 20, 2025, pending customary closing conditions [2]. - The offering is conducted under an effective shelf registration statement on Form F-3, filed with the SEC on April 28, 2025 [3]. Group 2: Company Overview - Robin Energy is an international ship-owning company that provides energy transportation services globally and currently owns one Handysize tanker vessel for carrying petroleum products [5].

Core Viewpoint - Citius Pharmaceuticals Inc. has successfully closed a registered direct offering, raising approximately $6 million, with potential additional proceeds of up to $9.8 million from short-term warrants [1][3]. Group 1: Offering Details - The offering consisted of 4,920,000 shares of common stock priced at $1.22 per share, along with short-term warrants to purchase an additional 9,840,000 shares [1][3]. - The short-term warrants have an exercise price of $1.00 per share, are immediately exercisable, and will expire 24 months from the initial exercise date [1][3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to support the commercial launch of LYMPHIR™, including milestone and regulatory payments, as well as general corporate purposes [3]. Group 3: Company Background - Citius Pharmaceuticals is focused on developing first-in-class critical care products, with LYMPHIR approved by the FDA for treating cutaneous T-cell lymphoma [6]. - The company also has a late-stage pipeline that includes Mino-Lok®, an antibiotic lock solution, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoid relief [6].

Core Viewpoint - Tempest Therapeutics, Inc. has entered into a definitive agreement for a registered direct offering of 739,000 shares at an offering price of $6.25 per share, expected to close around June 12, 2025, subject to customary conditions [1][2] Group 1: Offering Details - The offering is expected to generate approximately $4.6 million in gross proceeds before deducting fees and expenses [2] - H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering [2] - The shares are being offered under a "shelf" registration statement filed with the SEC, which was declared effective on January 27, 2025 [3] Group 2: Use of Proceeds - The net proceeds from the offering will primarily support a previously announced strategic alternative process, along with working capital and general corporate purposes [2] Group 3: Company Overview - Tempest Therapeutics is a clinical-stage biotechnology company focused on developing targeted and immune-mediated therapeutics for cancer treatment [5] - The company has a diverse portfolio of small molecule product candidates, ranging from early research to later-stage investigations in global studies [5]

Core Viewpoint - Acurx Pharmaceuticals, Inc. has successfully closed a registered direct offering of 2,745,000 shares at a price of $0.40 per share, along with a concurrent private placement of unregistered short-term warrants to purchase up to 8,235,000 shares at the same exercise price, aiming to raise approximately $1.1 million for working capital and general corporate purposes [1][2]. Group 1: Offering Details - The registered direct offering involved 2,745,000 shares of common stock priced at $0.40 each, with a concurrent issuance of short-term warrants for 8,235,000 shares [1]. - The total gross proceeds from the offering were approximately $1.1 million before deducting fees and expenses [2]. - The warrants will be exercisable upon stockholder approval and will expire 24 months after such approval [1]. Group 2: Regulatory and Compliance Information - The shares were offered under a "shelf" registration statement filed with the SEC, which became effective on July 11, 2022 [3]. - The warrants and underlying shares have not been registered under the Securities Act and may not be sold in the U.S. without an effective registration statement or applicable exemption [4]. Group 3: Company Overview - Acurx Pharmaceuticals is focused on developing a new class of small molecule antibiotics targeting difficult-to-treat bacterial infections, particularly Gram-positive bacteria [6]. - The lead product candidate, ibezapolstat, is ready for Phase 3 trials for treating C. difficile infections, with plans for international clinical trials this year [6]. - The company's pipeline includes antibiotic candidates for various serious bacterial infections, including MRSA and drug-resistant Streptococcus pneumoniae [6].

RONKONKOMA, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- SUNation Energy, Inc. (Nasdaq: SUNE), a leading provider of sustainable solar energy and backup power solutions for households, businesses, and municipalities, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 17,391,306 shares of the Company’s common stock (or common stock equivalents in lieu thereof) Series A warrants to purchase up to an aggregate 17,391,306 shares ...